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Background:  Inflammation plays a role in the response to metabolic stress in type 2 diabetes. However, the effects of rosiglita-
zone on inflammation of skeletal muscle have not been fully examined in type 2 diabetes. 
Methods:  We investigated the effects of the insulin-sensitizing anti-diabetic agent, rosiglitazone, on the progression of skeletal 
muscle inflammation in Otsuka Long-Evans Tokushima Fatty (OLETF) type 2 diabetic rats. We examined the expression of se-
rologic markers (serum glucose, insulin and free fatty acid) and inflammatory cytokines (tumor-necrosis factor-α, interleukin 
[IL]-1β and IL-6) in OLETF rats from early to advanced diabetic stage (from 28 to 40 weeks of age). 
Results:  Serum glucose and insulin concentrations were significantly decreased in rosiglitazone-treated OLETF rats compared 
to untreated OLETF rats. Rosiglitazone treatment significantly decreased the concentrations of serum inflammatory cytokines 
from 28 to 40 weeks of age. The mRNA expression of various cytokines in skeletal muscle was reduced in rosiglitazone-treated 
OLETF rats compared with untreated OLETF rats. Furthermore, rosiglitazone treatment resulted in the downregulation of 
ERK1/2 phosphorylation and NF-κB expression in the skeletal muscle of OLETF rats. 
Conclusion:  These results suggest that rosiglitazone may improve insulin sensitivity with its anti-inflammatory effects on skele-
tal muscle. 
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INTRODUCTION
Activation of inflammation by metabolic stress in diabetes is 
associated with insulin deficiency caused by destruction of pan-
creatic beta cells and insulin resistance in adipose tissue and liv-
er [1,2]. Adipocytes, which secrete several adipokines (leptin, re-
sistin, tumor-necrosis factor [TNF]-α, interleukin [IL]-6, and 
PAI-1), induce insulin resistance and inflammation throughout 
the entire body through a decrease in adiponectin [3]. The se-
cretion of cytokines caused by the activation of NF-κB also in-
duces insulin resistance in fatty liver [4].
  Some studies have reported that TNF-α is positively associ-
ated with insulin resistance, which is accompanied by diabetes 
and obesity [5,6]. In some studies that investigated the relation-
ship between insulin resistance and TNF-α, increases in TNF-α 
were found in the skeletal muscle of patients who had a high 
insulin resistance [7]. In addition, TNF-α inhibits activation 
of the insulin receptor tyrosine kinase by blocking insulin re-
ceptor substrate (IRS) phosphorylation and Akt substrate 160 
phosphorylation, which are important proteins in the insulin 
signaling pathway in skeletal muscle [8-10]. Based on these re-
sults, it seems that an increase in TNF-α is not just a byprod-
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uct of inflammation, but may directly influence inflammation 
of skeletal muscle.
  Thiazolidinedione (TZD) is an insulin sensitizer that func-
tions not only to enhance the effect of insulin by controlling 
gene transcription through binding with nuclear receptor per-
oxisome proliferator activated receptor (PPAR)-γ, but also to 
inhibit inflammation of adipose tissue, immunologic cells and 
blood vessels through several inflammatory pathways (STAT, 
AP-1 and NF-κB pathway) [11-13].
  In this study, we investigated the role of skeletal muscle in-
flammation in the pathogenesis of insulin resistance in type 2 
diabetes in the Otsuka Long Evans Tokushima Fatty (OLETF) 
rat, a well-known type 2 diabetes animal model. OLETF rats 
progress to hyperglycemia in postnatal week 18 and fibrosis of 
pancreatic beta cells in postnatal week 40 [14]. We also inves-
tigated whether the anti-inflammatory effect of rosiglitazone, 
which has been shown in adipose tissue and inflammatory cells, 
is also present in skeletal muscle.
METHODS
Laboratory animals
Five-week-old OLETF rats (n = 21) and Long-Evans Tokushi-
ma Otsuka (LETO) rats (n = 11) were obtained from the Ot-
suka Pharmaceutical Co. Ltd. (Tokushima, Japan). Each rat was 
housed in a separate cage and was fed animal feed. The cages 
were maintained at a constant temperature of 22 ± 2°C and the 
light-dark cycle was adjusted automatically every 12 hours. To 
extract tissues before the experiment, 5 rats from the OLETF 
group and 5 rats from the LETO group were sacrificed. Between 
the 28th and 40th weeks, LETO rats (n = 6) were fed normally, 
and OLETF rats were divided into a non-treated group (n = 8) 
and a rosiglitazone-treated (GlaxoSmithKline Pharmaceuti-
cals, Philadelphia, PA, USA) group (3 mg/kg body weight, n = 
8) (Fig. 1). At the 40th week, weight and urine glucose levels 
were measured, and the rats were sacrificed to collect gastroc-
nemius muscle samples. 
  The body weights of the animals were measured every 4 
days at 4 o’clock in the afternoon between the 8th and 40th 
weeks. 
Serologic tests
At the 28th and 40th weeks, fasting blood was extracted from 
the hearts of OLETF and LETO rats. Plasma was separated from 
whole blood and refrigerated at -70°C. Serum glucose level was 
measured by glucose oxidase reaction method using an enzyme 
reagent (Asan Pharmaceutical Co., Seoul, Korea). The concen-
tration of insulin was measured by enzyme-linked immuno-
sorbent assay (ELISA) kit (Shibayagi Co., Ishihara, Japan). The 
concentration of free fatty acids was measured by the kinetic 
alkaline picrate method using an enzyme reaction kit (Asan 
Pharmaceutical Co.). Homeostasis model assessment (HOMA)-
insulin resistance (IR) and HOMA-β (HOMA beta cell func-
tion) were estimated using the following formula: [Fasting in-
sulin (μIU/mL) × fasting plasma glucose (mmol/L)]/22.5; 
HOMA-β = 20°C fasting insulin (μU/mL)/fasting glucose (mg/
dL) – 63 [15].
 
Measurement of inflammatory cytokines 
At the 28th and 40th weeks, the concentrations of TNF-α, IL-
LETO (n = 11) 28 week (n = 5) 40 week (n = 6) No treated group
OLETF (n = 20) 28 week (n = 5)
40 week (n = 8) No treated group
40 week (n = 8) Rosiglitazone treated group
Fig. 1.  Experimental schedule in Otsuka Long-Evans Tokushima Fatty (OLETF) and Long-Evans Tokushima Otsuka (LETO) 
rats. 
Sacrifice for 1st sample
Rosiglitazone treatment (3 mg/kg)
Once a day / 12 weeks
Sacrifice for 2nd sample193
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1β and IL-6 were measured from the sampled blood plasma 
using an ELISA kit (eBioscience, San Diego, CA, USA).
Expression of inflammatory cytokine genes
To extract gastrocnemius muscle samples, the rats were sacri-
ficed by intraperitioneal injection of 2.5% tribromoethanol at 
the 28th and 40th weeks. The extracted gastrocnemius sam-
ples were immediately frozen with liquid nitrogen and ground 
with a homogenizer. Total RNA was separated from the ground 
tissues using TRIzol reagent. The cDNA was synthesized using 
oligo-(dT) primer and AccuScript
TM high fidelity 1ST strand 
cDNA synthesis kit (Stratagene) at 65°C for 5 minutes, at 42°C 
for 1 hour and at 70°C for 15 minutes. For the PCR reaction, 
10 × PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 0.1% 
Triton X-100), 250 μM dNTP mix, 1 U Taq polymerase (Taka-
ra) and a specific primer for each cytokine were mixed with 1 
μg cDNA. The reaction was incubated at 94°C for 30 seconds 
for denaturation, at 57-62°C for 30 seconds for annealing, and 
at 72°C for 30 seconds for extension. This cycle was repeated 
25-35 times. ACTIN was used for the comparison with PCR 
reaction. The primer sequences for the PCR reaction are shown 
below.
  Actin; Forward, 5’-TCA TGA AGT GTG ACG TTG ACA 
TCC GT-3’; Reverse, 5’-CCT AGA AGC ATT TGC GGT GCA 
CGA TG -3’, TNF- α ; Forward, 5’-AAA GCA TGA TCC GAG 
ATG TG-3’; Reverse, 5’-AGC AGG AAT GAG AAG AGG CT-
3’, IL-6: Forward, 5’-CCG GAG AGG AGA CTT CAC AG-3’; 
Reverse, 5’-AGA ATT GCC ATT GCA CAA C-3’, IL-1β; For-
ward, 5’-CAT CTT TGA AGA AGA GCC CG-3’; Reverse, 5’-
GGG ATT TCG TTG TTG CTT GT-3’.
Inflammatory signal molecules
Ground gastrocnemius muscle liquid, which was extracted 
from the 28th and 40th week, was washed twice with HBSS 
buffer, and then lysed on ice with RIPA buffer (50 mM HEP-
ES, pH 7.4, 150 mM NaCl, 1% deoxycholate, 1 mM EDTA, 1 
mM PMSF, 1 μg/mL aprotinin). To observe NF-κB expression, 
the nucleus was extracted using NE-PER nuclear and cytoplas-
mic extraction reagent (Pierce, Rockford, IL, USA). The protein 
was measured by the Bradford method. The same quantity (20 
μg) of protein was mixed with 2X sample buffer (100 mM Tris-
HCl, pH 6.8, 200 mM dithithreitol, 4% SDS, 0.2% bromophenol 
blue, 20% glycerol). Then, the mixture was separated with 10% 
SDS-PAGE. After electrophoresis, the protein was transferred 
to nitrocellulose membrane at 4°C, 30 V for 16 hours. The mem-
brane was blocked with 10% skim milk at room temperature 
for 1 hour, and then the membrane was reacted for 2 hours at 
room temperature with a dilution of monoclonal antibody for 
β-actin, ERK1/2 MAPK or NF-κB (Cell Signaling Technology; 
#9101, #3036); antibodies were diluted with Tris-buffered sa-
line containing 0.05% tween (TBS-T). The membrane was then 
washed three times with TBS-T. Then the membrane was re-
acted with HRP-conjugated anti-rabbit IgG secondary antibody 
at room temperature for an hour, and bands were visualized 
with an enhanced chemiluminescence kit and X-ray film (Am-
ersham Pharmacia Biotech, San Francisco, CA, USA).
Statistical analysis
All results are shown as the mean and standard deviation based 
on three experiments. Statistical analysis of the difference be-
tween groups was analyzed by one-way ANOVA (GraphPad 
Prism program; GraphPad Software Inc., San Diego, CA, USA) 
and Student t-test. A P value less than 0.05 was considered sta-
tistically significant.
RESULTS
Changes in body weight
The weights of the OLETF and LETO rats were measured ev-
ery 4 weeks between the 18th and 40th week. The weights of 
both OLETF and LETO rats decreased with time until the 36th 
week. An insignificant decrease in weight in normally fed OLETF 
rats was observed at the 40th week. The increase in the weight 
of the OLETF rats was greater than that of the LETO rats, re-
gardless of rosiglitazone administration. At the 36th week, the 
average weight of the LETO rats was 534.9 ± 7.7 g, while that 
of rosiglitazone-treated OLETF rats was 733.9 ± 18.6 g, and 
that of untreated OLETF rats was 681.1 ± 18.0 g. At the 40th 
week, the average weight of the LETO rats was 558.3 ± 8.7 g, 
while that of untreated OLETF rats was 655.7 ± 48.9 g and that 
of the rosiglitazone-treated OLETF rats increased up to 757.8 
± 19.0 g (Fig. 2). The weight gain of the rosiglitazone-treated 
OLETF rats was greater than that of the untreated OLETF rats 
at the 32nd week. However, the difference was not statistically 
significant until the 40th week.
Changes in serologic markers
To investigate the chemical changes related to the administra-
tion of rosiglitazone, blood was obtained from both OLETF 
and LETO rats at the 28th and 40th week. Concentrations of 194
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free fatty acid (FFA), insulin and glucose were measured from 
the plasma (Fig. 3). At the 28th week, the fasting glucose con-
centrations of the LETO and OLETF rats were 167.9 ± 40.1 
mg/dL and 229.8 ± 44.2 mg/dL, respectively. The glucose level 
was higher in the OLETF rats than in the LETO rats. At the 
40th week, the glucose level of the LETO rats was 164.5 ± 26.8 
mg/dL, while that of the rosiglitazone-treated OLETF rats was 
224.1 ± 42.5 mg/dL, and that of the untreated OLETF rats was 
276.7 ± 44.4 mg/dL. The glucose level of the rosiglitazone-
treated OLETF rats decreased significantly compared with that 
of untreated OLETF rats.
  At the 28th week, the insulin concentrations of the LETO 
rats and OLETF rats were 0.94 ± 0.1 ng/mL and 2.66 ± 0.4 ng/
mL, respectively. The insulin concentration of the OLETF rats 
increased more than that of the LETO rats (P < 0.05). At the 
40th week, the insulin concentration of the LETO rats was 1.89 
± 1.6 ng/mL, that of the rosiglitazone-treated OLETF rats was 
2.01 ± 1.4 ng/mL and that of the untreated OLETF rats was 1.89 
± 1.6 ng/mL. The insulin concentration decreased significantly 
in the rosiglitazone-treated group (P < 0.05, Fig. 3).
  There were no statistically significant changes in HOMA-β 
and HOMA-IR among the LETO rats, rosiglitazone-treated 
and untreated OLETF rats (data not shown). The mean values 
of HOMA-IR among the LETO rats, rosiglitazone-treated and 
untreated OLETF rats were 0.8 ± 0.35, 2.4 ± 1.05 and 1.83 ± 
Fig. 3.  Changes in concentration of serological markers in 
Long-Evans Tokushima Otsuka (LETO) and Otsuka Long-
Evans Tokushima Fatty (OLETF) rats. Glucose, insulin and 
free fatty acid in sera of LETO or OLETF rats were measured 
by colorimetric and enzymatic assay at 28 and 40 weeks. Val-
ues were represented as mean ± standard deviation. FFA, free 
fatty acid. 
aP < 0.05 and 
bP < 0.01 as compared to each group. 
ROSI is an abbreviation for rosiglitazone. 
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Fig. 2.  Changes of body weight in Long-Evans Tokushima 
Otsuka (LETO) and Otsuka Long-Evans Tokushima Fatty 
(OLETF) rats. Body weights were measured at 28, 32, 36, and 
40 weeks, and changes are represented as the average weights 
on indicated days. Values are presented as mean ± standard 
deviation. ROSI, rosiglitazone. 
aP < 0.001 as compared to 
LETO rats. 
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0.86, respectively. Insulin resistance increased more in untreated 
OLETF rats than in LETO rats. There was a trend of decreased 
insulin resistance in rosiglitazone-treated OLETF rats compared 
with untreated OLETF rats (data not shown).
  At the 28th week, the FFA concentrations of the LETO and 
OLETF rat groups were 484.8 ± 77.9 mg/dL and 311.8 ± 76.7 
mg/dL, respectively (Fig. 3). At the 40th week, the FFA concen-
tration of the LETO rats was 505.3 ± 82.7 mg/dL, that of the 
untreated OLETF rats was 276.1 ± 18.3 mg/dL and that of the 
rosiglitazone-treated OLETF rats was 280.1 ± 46.6 mg/dL. At 
the 40th week, the FFA level was lower in the OLETF group 
compared to the LETO group. In contrast, a decrease in the 
FFA level was not observed in the rosiglitazone-treated group 
compared with the untreated group.
Changes in inflammatory cytokines
Serum TNF-α concentrations at the 40th week were 261.9 ± 
8.3 pg/mL in the LETO rats, 613.5 ± 64.3 pg/mL in the untreat-
ed OLETF rats, and 282.1 ± 11.84 pg/mL in the rosiglitazone-
treated OLETF rats (Fig. 4). The TNF-α concentration of the 
OLETF rat group was significantly increased compared with 
that of the LETO rat group at the 40th week. In the OLETF rat 
group, TNF-α secretion was significantly decreased by rosigli-
tazone administration. 
  For IL-1β at the 40th week, the mean concentration in the 
LETO rat group was significantly lower than that in the un-
treated OLETF rat group (125.6 ± 7.9 pg/mL vs. 189.8 ± 30.6 
pg/mL, respectively). The IL-1β concentration of the rosiglita-
zone-treated OLETF rat group at the 40th week, was 137.8 ± 
5.7 pg/mL, which was significantly lower than that of the un-
treated group (Fig. 4). 
  For IL-6 at the 40th week, the mean concentration in the 
LETO rat group was significantly lower than that of the un-
treated OLETF rat group (261.8 ± 19.5 pg/mL vs. 906.5 ± 49.1 
pg/mL, respectively). The rosiglitazone-treated rats had signif-
icantly lower IL-6 levels (709.1 ± 61.2 pg/mL) compared with 
untreated rats (Fig. 4).
Changes of inflammatory cytokine gene expression in 
skeletal muscle
The gene expression of inflammatory cytokines in the OLETF 
rat group was higher than that of the LETO rat group (Fig. 5). 
Cytokine gene expression was lower in the rosiglitazone-treat-
ed OLETF rat group than in the untreated OLETF rat group, 
although the difference was not statistically significant.
Fig. 4.  Changes in inflammatory cytokine levels in Long-Ev-
ans Tokushima Otsuka (LETO) and Otsuka Long-Evans Toku-
shima Fatty (OLETF) rats. Tumor-necrosis factor (TNF)-α, in-
terleukin (IL)-1β, IL-6 levels in sera of LETO or OLETF rats 
were measured by enzyme-linked immunosorbent assay at 28 
and 40 weeks. Values are represented as the mean ± standard 
deviation. ROSI, rosiglitazone. 
aP < 0.05 and 
bP < 0.001 as 
compared to each group. 
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Changes in inflammatory signal molecules expression
To investigate the effects of rosiglitazone administration on 
the inflammatory pathway, expression of signaling molecules 
in ERK1/2 MAPK and NF-κB pathways was examined in skel-
etal muscle tissue of LETO and OLETF rats by Western blot 
(Fig. 6). The phosphorylation of ERK1/2 MAPK of the LETO 
rats was shown to increase compared with that in the OLETF 
rats. The phosphorylation of ERK1/2 was lowered by rosiglita-
zone treatment in OLETF rats (Fig. 6A). In addition, for NF-
κB, there was an increase in the expression of the NF-κB p65 
subunit in the nucleus in OLETF rats, and this was decreased 
by administration of rosiglitazone (Fig. 6B).
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Fig. 5.  Changes in inflammatory cytokine gene expression in Long-Evans Tokushima Otsuka (LETO) and Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats. The expression of Tumor-necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 mRNA in skeletal 
muscle tissues of LETO and OLETF mice were determined by RT-PCR at 40 weeks. There are no significant differences between 
the groups. This is a representative figure from three independent experiments. ROSI is an abbreviation for rosiglitazone.
Fig. 6.  Changes in levels of in-
flammatory signaling mole-
cules in Long-Evans Tokushi-
ma Otsuka (LETO) and Otsuka 
Long-Evans Tokushima Fatty 
(OLETF) rats. (A) ERK1/2 
phosphorylation in cytosol and 
(B) NF-κB p65 expression in 
nucleus of skeletal muscle tis-
sues were determined by West-
ern blot analysis at 40 weeks. 
This is a representative figure 
from three independent exper-
iments. There are no significant 
differences between the groups. 
ROSI is an abbreviation for 
rosiglitazone. 
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DISCUSSION
Skeletal muscle mainly uses glucose as an energy fuel. Insulin 
resistance of muscle, caused by accumulation of fatty acid and 
reduced expression of glucose transporter, plays a significant 
role in the pathogenesis of type 2 diabetes. Normal muscle tis-
sues are not involved in the inflammatory process, except for 
in the condition of muscle atrophy, which is seen in cachexia 
or chronic inflammation of muscles. Human leukocyte anti-
gen (HLA) class Ι, HLA class ΙΙ and secretion of inflammatory 
cytokine increase when a proinflammatory stimulus is given 
to normal muscle tissues [15]. TNF-α mRNA expression after 
delivery was higher in gestational diabetes patients than in pa-
tients with normal glucose tolerance, and this was also related 
to insulin resistance [16]. The inflammatory process was ob-
served in the skeletal muscle of diabetes patients, in whom chron-
ic systemic inflammation is known to be present. However, the 
degree of inflammation of skeletal muscle in relation to insulin 
resistance in diabetes has never been shown. An increase in 
adipose tissue caused by obesity activates the JNK and NF-κB 
pathway, and also induces inflammation in liver through se-
cretion of several inflammatory cytokines. This phenomenon is 
known to contribute to hyperglycemia through inappropriate 
inhibition of gluconeogenesis in liver [4]. Our hypothesis was 
that increased inflammation in skeletal muscle tissues of dia-
betes patients contributes to increases in insulin resistance in 
type 2 diabetes, just as there is inflammation in liver tissues in 
diabetes patients. Then, we examined inflammation markers 
in skeletal muscle tissue and plasma in OLETF rats, which is 
an animal model of type 2 diabetes.
  In this experiment, at the 40th week, gene expression of in-
flammatory cytokines (TNF-α, IL-1β and IL-6) and expres-
sion of ERK1/2 MAPK and NF-κB in the gastrocnemius mus-
cle was increased in OLETF rats compared to LETO rats. In-
creased expression of the transcriptional factors of inflamma-
tory pathways such as ERK1/2 MAPK and IκB/NF-κB in the 
nucleus is known to be involved in the pathogenesis of insulin 
resistance in skeletal muscle. There have been other studies 
that observed activation of NF-κB caused by reduction of in-
hibitor of κBβ (IκB) at skeletal muscle of type 2 diabetes pa-
tients is related with insulin resistance [17]. Activation of NF-
κB in adipose tissue, which is caused by TNF-α stimulus, in-
duces insulin resistance through inhibition of insulin signaling 
[18,19].
  The mode of action of TZD has not verified completely, but 
it is known to bind with PPAR-γ selectively in adipose tissue, 
muscle tissue and liver tissue, which are the target organs of 
insulin action. It accelerates gene expression of glucose trans-
porter (GLUT)-1, GLUT-4 and activates differentiation of adi-
pose tissue and inhibits expression of TNF-α, hepatic glucoki-
nase. Finally, it improves insulin resistance and recovers glucose 
homeostasis in the human body. In this experiment, we found 
that rosiglitazone plays a role in reducing glucose and insulin 
levels among various biochemical markers. We observed an 
improvement in insulin resistance, although there was not an 
increase in insulin secretion ability. Rosiglitazone-treated OLETF 
rats gained their weight gradually until the 40th week, while 
untreated OLETF rats lost weight after the 40th week, which is 
considered to be a negative side effect of rosiglitazone.
  It is known that TZDs have an anti-inflammatory effect 
through inhibition of the transcription process in the inflam-
mation pathway. PPAR-γ expression was abundantly found in 
adipose tissue, macrophages and endothelial cells of blood 
vessels and it was also reported that TZDs decrease NF-κB ex-
pression at colonic epithelial cells in inflammatory bowel dis-
ease [20]. However, its anti-inflammatory effect on skeletal mus-
cle, which is the target organ of insulin action, has not been clar-
ified yet. It is known that rosiglitazone has an effect on several 
inflammatory pathways, such as STAT, AP-1, and NF-κB [21]. 
Rosiglitazone inhibits inflammatory cytokine secretion at mono-
cytes and macrophages by interruption of NF-κB in these inflam-
matory pathways [11-13]. In our study, at the 40th week, in-
flammatory cytokines (TNF-α, IL-1β and IL-6) were reduced 
significantly in rosiglitazone-treated OLETF rats in compari-
son to untreated OLETF rats. The expression of inflammatory 
cytokine mRNA (TNF-α, IL-1β and IL-6) was found to be de-
creased in rosiglitazone-treated OLETF rats. The inflammato-
ry pathways of ERK/MAPK and NF-κB were inhibited at skele-
tal muscle of rosiglitazone-treated OLETF rats. This study result 
shows that rosiglitazone, which increases the expression of 
glucose transporters and to decrease the accumulation of lip-
ids at skeletal muscle [22,23], also interrupts the expression of 
inflammatory cytokine (TNF-α, IL-1β and IL-6) mRNA and 
thus contributes to the inhibition of inflammatory pathway of 
ERK/MAPK and NF-κB at skeletal muscle [24,25]. However, 
there is still doubt that only inhibition of NF-κB pathway at 
skeletal muscle is sufficient to improve insulin resistance in the 
whole body, because a previous study showed an opposite result 
based on an experiment with muscle-specific IKK2 (IκB kinase) 
knockout mice [26]. The anti-inflammatory effect of rosiglita-198
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zone on insulin resistance must be studied more extensively 
through the measurement of GLUT-4 expression, glucose re-
ceptor and IRS-1 in the skeletal muscle of OLETF rats. In ad-
dition, it is necessary to investigate whether Rel translocation, 
Rel DNA binding and IκBα degradation, which are considered 
to be involved in the pathogenetic mechanisms that inhibits 
NF-κB pathway, are related to the anti-inflammatory effect of 
rosiglitazone.
  In this experiment, we did not observe improvement in FFA 
level, which is a well-known effect of rosiglitazone in other tis-
sues. Although the weight of OLETF rats increased, the FFA 
level did not increase in the OLETF rats compared to the LETO 
rats between the 28th and 40th week. Thus, we were unable to 
detect an improvement in lipids. However, the anti-inflamma-
tory effect of rosiglitazone was observed. It has already been 
shown that low dose rosiglitazone exerts an anti-inflammatory 
effect independently of improvements in lipid and insulin re-
sistance in type 2 diabetes [27]. 
  In this study, we observed the relationship between changes 
in skeletal muscle inflammation and chronic inflammation in 
hyperglycemic status. Rosiglitazone directly inhibited the in-
flammatory process in the skeletal muscle in our rat model, 
which is considered to be a component of the pathogenesis of 
insulin resistance in skeletal muscle. These effects might help 
to improve insulin resistance, not only in skeletal muscle, but 
also in the entire body.
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